ArticleVaccine: X2022

Safety and immunogenicity of a single dose, live-attenuated 'tetravalent dengue vaccine' in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial.

Lalitendu Mohanty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.